Improving Adherence to Weight-Loss Medication (Liraglutide 3.0 mg) Using Mobile Phone Text Messaging and Healthcare Professional Support.


Journal

Obesity (Silver Spring, Md.)
ISSN: 1930-739X
Titre abrégé: Obesity (Silver Spring)
Pays: United States
ID NLM: 101264860

Informations de publication

Date de publication:
10 2020
Historique:
received: 21 01 2020
revised: 01 05 2020
accepted: 05 06 2020
pubmed: 10 9 2020
medline: 31 3 2021
entrez: 9 9 2020
Statut: ppublish

Résumé

Adherence to weight-loss medication is suboptimal, leading to poor health outcomes. Short message service (SMS) can potentially improve adherence. A total of 3,994 participants with overweight or obesity in Australia receiving Saxenda® (liraglutide 3.0 mg) were enrolled from September 1, 2017, to February 28, 2018, through doctors, pharmacists, or websites and were randomly assigned to receive none, three, or five SMS per week. Participants were additionally offered a face-to-face consultation with a diabetes educator or a call from a dietitian. Medication adherence was measured as whether the total scripts claimed were at least as many as the total claims expected by March 31, 2018, and was modeled adjusting for age, sex, baseline BMI, residential region, enrolment channel, the total number of SMS, and additional patient support. Participants receiving five SMS (OR, 6.25; 95% CI: 4.28-9.12) had greater adherence than those receiving three SMS (OR, 3.67; 95% CI: 2.67-5.03) or zero SMS per week. The effectiveness of SMS on adherence decreased as participants received more SMS over time. Moreover, the odds of adhering to liraglutide were higher for participants enrolled with pharmacists compared with those enrolled with doctors (OR, 2.28; 95% CI: 1.82-2.86) and for participants who received a face-to-face consultation (OR, 3.10; 95% CI: 1.82-5.29) or a call (OR, 1.31; 95% CI: 1.02-1.68) compared with those who received no extra support. Integration of SMS into routine clinical practice should consider not only the frequency and content of reminders but also additional patient support to achieve higher and more sustained adherence to medication and health behavior changes.

Sections du résumé

BACKGROUND
Adherence to weight-loss medication is suboptimal, leading to poor health outcomes. Short message service (SMS) can potentially improve adherence.
METHODS
A total of 3,994 participants with overweight or obesity in Australia receiving Saxenda® (liraglutide 3.0 mg) were enrolled from September 1, 2017, to February 28, 2018, through doctors, pharmacists, or websites and were randomly assigned to receive none, three, or five SMS per week. Participants were additionally offered a face-to-face consultation with a diabetes educator or a call from a dietitian. Medication adherence was measured as whether the total scripts claimed were at least as many as the total claims expected by March 31, 2018, and was modeled adjusting for age, sex, baseline BMI, residential region, enrolment channel, the total number of SMS, and additional patient support.
RESULTS
Participants receiving five SMS (OR, 6.25; 95% CI: 4.28-9.12) had greater adherence than those receiving three SMS (OR, 3.67; 95% CI: 2.67-5.03) or zero SMS per week. The effectiveness of SMS on adherence decreased as participants received more SMS over time. Moreover, the odds of adhering to liraglutide were higher for participants enrolled with pharmacists compared with those enrolled with doctors (OR, 2.28; 95% CI: 1.82-2.86) and for participants who received a face-to-face consultation (OR, 3.10; 95% CI: 1.82-5.29) or a call (OR, 1.31; 95% CI: 1.02-1.68) compared with those who received no extra support.
CONCLUSIONS
Integration of SMS into routine clinical practice should consider not only the frequency and content of reminders but also additional patient support to achieve higher and more sustained adherence to medication and health behavior changes.

Identifiants

pubmed: 32902905
doi: 10.1002/oby.22930
pmc: PMC7589266
doi:

Substances chimiques

Hypoglycemic Agents 0
Liraglutide 839I73S42A

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1889-1901

Informations de copyright

© 2020 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society (TOS).

Références

Pharmacotherapy. 2000 Aug;20(8):941-9
pubmed: 10939555
PLoS One. 2016 Jan 25;11(1):e0147735
pubmed: 26808440
Health Informatics J. 2012 Dec;18(4):235-50
pubmed: 23257055
Obes Res Clin Pract. 2016 Nov - Dec;10(6):680-691
pubmed: 26992569
Perm J. 2018 Jul 5;22:18-033
pubmed: 30005722
JAMA Intern Med. 2016 Mar;176(3):340-9
pubmed: 26831740
J Med Internet Res. 2009 Jan 13;11(1):e1
pubmed: 19141433
BMJ Open. 2013 Dec 17;3(12):e003950
pubmed: 24345901
J Eat Disord. 2017 May 15;5:14
pubmed: 28515933
Arch Intern Med. 1993 Aug 23;153(16):1863-8
pubmed: 8250647
J Am Diet Assoc. 1999 Jan;99(1):66-71
pubmed: 9917734
BMJ Open Diabetes Res Care. 2018 May 5;6(1):e000512
pubmed: 29755756
J Behav Med. 2016 Apr;39(2):201-13
pubmed: 26563148
J Eat Disord. 2017 May 1;5:15
pubmed: 28469914
Diabetes Res Clin Pract. 2011 Nov;94(2):269-75
pubmed: 21907442
Fam Pract Manag. 2013 Mar-Apr;20(2):25-30
pubmed: 23547611
BMJ. 2007 Dec 8;335(7631):1194-9
pubmed: 18006966
J Manag Care Spec Pharm. 2014 Jul;20(7):691-700
pubmed: 24967522
Br J Nutr. 2016 Dec;116(11):1974-1983
pubmed: 27976604
Cochrane Database Syst Rev. 2002;(2):CD000011
pubmed: 12076376
AIDS. 2011 Mar 27;25(6):825-34
pubmed: 21252632
J Am Med Inform Assoc. 2012 Sep-Oct;19(5):696-704
pubmed: 22534082
Am J Manag Care. 2003 Feb;9(2):155-71
pubmed: 12597603
J Med Internet Res. 2017 May 26;19(5):e147
pubmed: 28550001
J Clin Epidemiol. 2001 Dec;54 Suppl 1:S57-60
pubmed: 11750211
Mayo Clin Proc. 2018 Mar;93(3):351-359
pubmed: 29502565
Sleep Med Rev. 2008 Aug;12(4):289-98
pubmed: 18485764
Am J Med. 2013 Nov;126(11):1002-9
pubmed: 24050486
J Adv Nurs. 2014 Sep;70(9):1932-1953
pubmed: 24689978

Auteurs

Ang Li (A)

Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, Central Clinical School, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.
Sydney Health Economics Collaborative, Sydney Local Health District, Camperdown, New South Wales, Australia.

Michelle Cunich (M)

Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, Central Clinical School, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.
Sydney Health Economics Collaborative, Sydney Local Health District, Camperdown, New South Wales, Australia.

Nicholas Fuller (N)

Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, Central Clinical School, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.

Katrina Purcell (K)

Novo Nordisk Pharmaceuticals Pty. Ltd., Baulkham Hills, New South Wales, Australia.

Allanah Flynn (A)

Novo Nordisk Pharmaceuticals Pty. Ltd., Baulkham Hills, New South Wales, Australia.

Ian Caterson (I)

Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, Central Clinical School, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH